DB
CRNX icon

Danske Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Danske Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$4.66K – 1263
2025
Q4 		$4.66K Hold
100
– – ﹤0.01% 1368
2025
Q3 		$4.17K Hold
100
– – ﹤0.01% 1327
2025
Q2 		$2.88K Hold
100
– – ﹤0.01% 1390
2025
Q1 		$3.35K Hold
100
– – ﹤0.01% 1217
2024
Q4 		$5.11K Sell
100
-600
-86% -$33.6K ﹤0.01% 1198
2024
Q3 		$35.8K Buy
+700
New +$36.1K ﹤0.01% 1259

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Danske Bank's CRNX Position: Q1 2026 in Review

Danske Bank sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 100 shares — an estimated $4.66K sold.

Danske Bank first reported a position in CRNX in Q3 2024 and held it in 6 quarters. The position peaked at $35.8K in Q3 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Danske Bank reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Danske Bank sold 100 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $4.66K.
  • Danske Bank first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Danske Bank's Crinetics Pharmaceuticals position peaked at $35.8K in Q3 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.